全文获取类型
收费全文 | 1236936篇 |
免费 | 76522篇 |
国内免费 | 2005篇 |
专业分类
耳鼻咽喉 | 17918篇 |
儿科学 | 35995篇 |
妇产科学 | 32105篇 |
基础医学 | 174618篇 |
口腔科学 | 37231篇 |
临床医学 | 104012篇 |
内科学 | 236694篇 |
皮肤病学 | 27154篇 |
神经病学 | 94957篇 |
特种医学 | 53529篇 |
外国民族医学 | 200篇 |
外科学 | 199717篇 |
综合类 | 19910篇 |
现状与发展 | 1篇 |
一般理论 | 271篇 |
预防医学 | 82642篇 |
眼科学 | 29068篇 |
药学 | 94421篇 |
5篇 | |
中国医学 | 2547篇 |
肿瘤学 | 72468篇 |
出版年
2018年 | 14600篇 |
2017年 | 12594篇 |
2016年 | 13438篇 |
2015年 | 16137篇 |
2014年 | 18840篇 |
2013年 | 24998篇 |
2012年 | 39417篇 |
2011年 | 35748篇 |
2010年 | 20614篇 |
2009年 | 20730篇 |
2008年 | 32928篇 |
2007年 | 35323篇 |
2006年 | 36222篇 |
2005年 | 43070篇 |
2004年 | 43252篇 |
2003年 | 38153篇 |
2002年 | 33105篇 |
2001年 | 62305篇 |
2000年 | 62465篇 |
1999年 | 55141篇 |
1998年 | 11976篇 |
1997年 | 10287篇 |
1996年 | 10208篇 |
1995年 | 9848篇 |
1994年 | 9133篇 |
1993年 | 8373篇 |
1992年 | 42727篇 |
1991年 | 41421篇 |
1990年 | 40519篇 |
1989年 | 39243篇 |
1988年 | 35799篇 |
1987年 | 34846篇 |
1986年 | 32647篇 |
1985年 | 30956篇 |
1984年 | 21902篇 |
1983年 | 18438篇 |
1982年 | 9224篇 |
1979年 | 20255篇 |
1978年 | 13545篇 |
1977年 | 11349篇 |
1976年 | 9885篇 |
1975年 | 11812篇 |
1974年 | 14256篇 |
1973年 | 13260篇 |
1972年 | 12765篇 |
1971年 | 12252篇 |
1970年 | 11551篇 |
1969年 | 10906篇 |
1968年 | 9970篇 |
1967年 | 9155篇 |
排序方式: 共有10000条查询结果,搜索用时 67 毫秒
1.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
2.
3.
Yilmaz Hülya Fırtına Sinem Sarıtaş Merve Sayitoğlu Müge Ar Muhlis Cem 《Immunologic research》2022,70(6):811-816
Immunologic Research - Hyper immunoglobulin M (HIGM) syndrome is a rare disorder of the immune system with impaired antibody functions. The clinical picture of the patients varies according to the... 相似文献
4.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
5.
Clinical Rheumatology - Aimed to evaluate the time elapsed between the onset of early symptoms and the diagnosis of fibromyalgia syndrome (FMS), the delays in diagnosis and frequent physician... 相似文献
6.
S. Harrogate J. Barnes K. Thomas A. Isted G. Kunst S. Gupta S. Rudd T. Banerjee R. Hinchliffe R. Mouton 《Anaesthesia》2023,78(11):1393-1408
Tobacco smoking is associated with a substantially increased risk of postoperative complications. The peri-operative period offers a unique opportunity to support patients to stop tobacco smoking, avoid complications and improve long-term health. This systematic review provides an up-to-date summary of the evidence for tobacco cessation interventions in surgical patients. We conducted a systematic search of randomised controlled trials of tobacco cessation interventions in the peri-operative period. Quantitative synthesis of the abstinence outcomes data was by random-effects meta-analysis. The primary outcome of the meta-analysis was abstinence at the time of surgery, and the secondary outcome was abstinence at 12 months. Thirty-eight studies are included in the review (7310 randomised participants) and 26 studies are included in the meta-analysis (5969 randomised participants). Studies were pooled for subgroup analysis in two ways: by the timing of intervention delivery within the peri-operative period and by the intensity of the intervention protocol. We judged the quality of evidence as moderate, reflecting the degree of heterogeneity and the high risk of bias. Overall, peri-operative tobacco cessation interventions increased successful abstinence both at the time of surgery, risk ratio (95%CI) 1.48 (1.20–1.83), number needed to treat 7; and 12 months after surgery, risk ratio (95%CI) 1.62 (1.29–2.03), number needed to treat 9. More work is needed to inform the design and optimal delivery of interventions that are acceptable to patients and that can be incorporated into contemporary elective and urgent surgical pathways. Future trials should use standardised outcome measures. 相似文献
7.
8.
9.
Münch F. Purbojo A. Wenzel F. Kohl M. Dittrich S. Rauh M. Zimmermann R. Kwapil N. 《Der Anaesthesist》2022,71(11):882-892
Die Anaesthesiologie - Die Transfusion von Erythrozytenkonzentraten (EK) ist mit verschiedenen Nebenwirkungen assoziiert, die u. a. durch Lagerungsschäden an Erythrozyten hervorgerufen... 相似文献
10.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097